United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $575.40, for a total value of $5,466,300.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $23,311,180.20. The trade was a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $562.09 on Friday. The business’s 50 day simple moving average is $565.98 and its two-hundred day simple moving average is $515.55. The firm has a market cap of $23.86 billion, a P/E ratio of 20.75, a PEG ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.63 EPS. On average, equities analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UTHR. Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Finally, UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics said it will present at the Jefferies Global Healthcare Conference, keeping the company visible to investors and highlighting ongoing engagement with the healthcare investing community. Article Title
• Positive Sentiment: The company also shared updates on its PHINDER screening study and its xenokidney/EXTEND trial, which could support the long-term growth story if the clinical programs continue to progress. Article Title Article Title
• Neutral Sentiment: The stock remains supported by a generally constructive analyst backdrop, with several firms maintaining buy or outperform ratings and some raising price targets, which can help offset near-term concerns.
• Neutral Sentiment: Short-interest data showed no meaningful change in available reported shares, so this does not appear to be a major trading catalyst.
• Negative Sentiment: CEO Martine Rothblatt sold additional United Therapeutics shares, following another recent sale, and CFO James Edgemond also sold stock. Multiple insider sales can weigh on investor sentiment, especially after the company’s recent earnings miss. Article Title Article Title
• Negative Sentiment: United Therapeutics recently reported quarterly EPS and revenue below expectations, which remains an overhang on the shares despite the company’s strong profitability.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the company. Arjuna Capital lifted its position in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Clearstead Advisors LLC lifted its position in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares in the last quarter. Sage Rhino Capital LLC lifted its position in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC lifted its position in United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. lifted its position in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.